Siemens Healthineers unveils brain health biomarker assays
Siemens Healthineers has expanded its brain health research tools with the launch of fully automated assays for phosphorylated tau 217 and Brain Derived Tau, now available for research use.
Siemens Healthineers announced its brain health research capabilities are expanding, with the launch of the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays. Both assays are now available for research use only.
The blood tests from Siemens Healthineers offer researchers chemiluminescent immunoassays to provide a quantitative measurement of brain-derived phosphorylated tau 217 (p-tau217) and Brain Derived Tau (BD tau) and are run on the widely installed Atellica Solution IM and Atellica CI Analyzers. Blood-based biomarker testing offers a less-invasive method compared to cerebrospinal fluid which requires a lumbar puncture.
